Whitlock RH, et al. - Researchers performed a retrospective cohort study involving adults in Manitoba, Canada, with type 2 diabetes, who were receiving monotherapy prescription for metformin or a sulfonylurea, and a serum creatinine measurement from April 1, 2006, to March 31, 2017, in order to contrast the safety of metformin vs sulfonylureas in people with type 2 diabetes by chronic kidney disease (CKD) stage. A total of 21,996 people were involved in this cohort study (19,990 metformin users and 2006 sulfonylurea users). Findings revealed that in comparison with sulfonylureas, the use of Metformin was correlated with a lower risk for all-cause mortality (hazard ratio [HR], 0.48), cardiovascular events (HR, 0.67), and major hypoglycemic episodes (HR, 0.14). Although the appearance of CKD attenuated the mortality profit, metformin might be a safer option to sulfonylureas in people with CKD.